Clinical Trials
43 trialsNCT01142388 2026-05-29
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06535607 2026-05-26
eVOLVE-02
AstraZeneca
Phase 2 Recruiting
NCT07559045 2026-04-30
Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital of Zunyi Medical University
Phase 2 Recruiting
NCT06143748 2026-04-23
EC-CRT-006
Sun Yat-sen University
Phase 2 Active not recruiting
NCT07481058 2026-03-20
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT07039162 2026-02-27
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
China Medical University Hospital
Phase 2 Recruiting
NCT05189730 2025-11-20
ETNT
Sichuan Cancer Hospital and Research Institute
Phase 2 Active not recruiting
NCT04929392 2025-09-04
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT06637163 2025-04-17
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT04804696 2025-02-21
Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Terminated
NCT05520619 2024-11-18
EC-CRT-002
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05490719 2024-05-21
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04568200 2024-01-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Completed
NCT02916511 2023-12-22
ESO-Shanghai9
Fudan University
Phase 2 Completed
NCT04764227 2023-08-03
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
Fudan University
Phase 2 Active not recruiting
NCT05281003 2023-07-13
HYPERION
Fudan University
Phase 2 Recruiting
NCT04389177 2023-04-10
Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT02976909 2023-02-17
Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Completed
NCT03762564 2022-12-08
RAMOS
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT05522894 2022-08-31
AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC
ChineseAMS
Phase 2 Unknown
NCT04625543 2022-04-26
Neoadjuvant Immunotherapy to ESCC
Qilu Hospital of Shandong University
Phase 2 Withdrawn
NCT05322499 2022-04-11
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05044728 2021-09-16
Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT04063683 2021-08-24
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.
Henan Cancer Hospital
Phase 2 Unknown
NCT03791905 2021-03-23
PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT03116152 2021-02-03
Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Completed
NCT04225364 2021-02-02
Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma
Guangzhou Institute of Respiratory Disease
Phase 2 Completed
NCT00006472 2020-08-18
Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
Medstar Health Research Institute
Phase 2 Terminated
NCT03579004 2018-07-06
Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer
Russian Academy of Medical Sciences
Phase 2 Unknown
NCT03126708 2018-01-04
Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Unknown
NCT00816634 2017-05-01
XP versus XT
Samsung Medical Center
Phase 2 Unknown
NCT00069953 2017-02-17
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00022139 2016-12-07
Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02586753 2015-10-26
Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus
Mianyang Central Hospital
Phase 2 Unknown
NCT00021320 2014-05-09
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT02016274 2013-12-19
Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer
Peking University
Phase 2 Unknown
NCT00009880 2013-07-19
Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00003087 2013-06-25
Combination Chemotherapy, Radiation Therapy and Surgery in Treating Patients With Cancer of the Esophagus
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00006245 2013-06-24
Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005599 2013-06-21
Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01688700 2012-09-20
Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT00066716 2009-12-08
Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus
Weill Medical College of Cornell University
Phase 2 Completed
NCT00003326 2008-07-24
Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus
National Cancer Institute (NCI)
Phase 2 Unknown